PetVivo (PETV) Investor update summary

Company overview and strategy

• Focuses on innovative medical devices and therapeutics for companion animals, leveraging technology initially developed for humans and funded by NIH and Department of Defense.

• Operates through four subsidiaries: PetVivo.ai (veterinary innovation and pet owner engagement), PetVivo Animal Health (product portfolio including Spryng and PrecisePRP), partnership with PiezoBio (nanofiber technology), and Gel-Del Technologies (manufacturing to human medical device standards).

• PetVivo.ai aims to reduce veterinary customer acquisition costs and streamline clinic operations through targeted technology.

Product innovation and clinical feedback

• Spryng and PrecisePRP are positioned as multimodal solutions for osteoarthritis, providing alternatives to pharmaceuticals and surgery.

• Spryng mimics natural joint tissue, improves lubrication, and acts as a scaffold to promote healthier joint environments, reducing inflammation and improving mobility.

• Veterinarians report positive outcomes, especially for pets where surgery is not feasible, and use Spryng both as a treatment and preventive measure.

• The product is valued for enhancing quality of life and offering holistic options, with broad support from general practitioners, surgeons, and specialists.

Market trends and commercial strategy

• Industry trends favor reducing pharmaceutical use due to side effects; Spryng offers a neutral, long-term alternative.

• Insurance companies are recognizing the cost-saving potential of advanced technologies like Spryng, supporting earlier adoption.

• Distribution strategy includes partnerships with all major U.S. veterinary distributors and expansion into the U.K., EU, Mexico, and Canada.

• The approach ensures product availability through preferred channels globally, leveraging exposure at major industry conferences.